Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in lymphoma
- New trial
Lymphoma
Phase 1 trial lisocabtagene maraleucel, a CD19-directed CAR-T for frontline PCNSL.
This study evaluates the safety and efficacy of lisocabtagene maraleucel as first-line treatment in transplant-ineligible adults with Primary CNS Lymphoma in investigational and expansion arms. Sponsored by Juno…
NCT07015242 Exploratory - Trial result Spotlight
Lymphoma
Epcoritamab (CD20×CD3 bispecific, subcutaneous) tops chemoimmunotherapy and other bispecifics (mosunetuzumab and odronextamab) in ≥2-line relapsed follicular lymphoma
In a matching-adjusted indirect comparison of the EPCORE-NHL-1 FL cohort (≈127 pts) against real-world standard of care/chemoimmunotherapy (SOC/CIT) from SCHOLAR-5 and trial arms of two CD20xCD3 bispecific antibodies…
- Trial result
Lymphoma
Emavusertib (IRAK4i) + Ibrutinib Achieves 4/6 Deep Responses in MyD88-mutant R/R PCNSL, with CSF Levels Rising Two-fold at 200 mg BID
Emavusertib, an oral, brain-penetrant IRAK4 inhibitor, was paired with ibrutinib 560 mg QD in the phase 1/2 TakeAim‐Lymphoma trial (NCT03328078). Among seven patients with relapsed/refractory primary CNS-lymphoma who…
NCT03328078 - Trial result
Lymphoma
KITE-363 Dual-Target (CD19 + CD20) CAR-T Hits 87% ORR and 78% CR in Dose-Level-3 LBCL After ≥2 Lines
KITE-363 is an autologous bicistronic CAR-T engineered to co-recognize CD19 and CD20, aiming to head off CD19-negative relapse. In the phase 1 NCT04989803 trial, 37 heavily pre-treated large B-cell-lymphoma patients…
NCT04989803 - Trial result
Lymphoma
Brentuximab Vedotin + Nivolumab Clears ctDNA in 100% of Early-Stage Hodgkin Lymphoma by End of Therapy
In the SGN35-027 Part C Phase 2 study (NCT03646123), 36 stage I–II cHL (classic or early-state Hodgkin lymphoma) patients received brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine every 28 days. Baseline…
NCT03646123 - Trial result
Lymphoma
Acimtamig + AlloNK Delivers 86% ORR and 55% CR in Heavily Pretreated Classical Hodgkin Lymphoma
Acimtamig (AFM13) is a tetravalent CD30/CD16 innate-cell engager that redirects NK cells; AlloNK (AB-101) is an off-the-shelf cord-blood NK-cell product co-infused with IL-2. In the completed dose-finding stage of…
NCT05883449 - New trial
Lymphoma
Phase II Obinutuzumab CD20-targeted mAb Trial in Relapsed or Refractory Follicular Lymphoma
This randomized Phase II trial by the National Cancer Institute compares obinutuzumab used alone or combined with umbralisib, lenalidomide, or standard chemotherapy to treat patients with grade I–IIIa relapsed or…
NCT03269669 - New trial
Lymphoma
Phase 1 BAFFR-CAR T Cells: BAFF-R-directed immunotherapy for relapsed B-cell NHL
This study evaluates BAFFR-targeted CAR T cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas—including diffuse large B-cell, follicular, marginal zone, and mantle cell subtypes—using…
NCT05370430 - New trial
Lymphoma
Phase 2 Trial of Glofitamab (CD20/CD3 Bispecific) in MRD+ LBCL
MD Anderson is recruiting patients with large B-cell lymphoma who achieved CR after first-line therapy but remain MRD-positive to assess the safety and recurrence prevention potential of glofitamab, a CD20 and CD3…
NCT06670105 - New trial
Lymphoma
A Phase II Study of Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma: A Risk Adapted Approach
This trial evaluates the efficacy of pirtobrutinib, a BTK inhibitor, in combination with rituximab for patients with newly diagnosed marginal zone lymphoma using a risk-adapted approach. Sponsored by the University…
NCT06390956 - New trial
Lymphoma
Phase II Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
This phase II study will evaluate epcoritamab—a bispecific CD20/CD4 antibody—as a first-line treatment for newly diagnosed MZL, with patients receiving up to 12 cycles over 28-day cycles for a maximum of 3 years.
NCT06796998 - Trial result
Lymphoma
Effective Chemo-Free Therapy: Brentuximab Vedotin Plus Nivolumab Yields Durable Response in Older Hodgkin Lymphoma
In this phase II study targeting patients over 60 or those unfit for standard chemotherapy, the combination of brentuximab vedotin (BV) and nivolumab demonstrated promising long-term outcomes. With a median follow-up…
- New trial
Lymphoma
PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed/Refractory Follicular Lymphoma
University of Washington is testing the combination of pirtobrutinib, a BTK inhibitor, and mosunetuzumab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory grade 1-3a follicular lymphoma patients.…
NCT06948786 - New trial
Lymphoma
Phase 2 Study: Epcoritamab and Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
University of Miami is investigating whether the combination of epcoritamab and loncastuximab tesirine can safely and effectively reduce lymphoma cells in patients with relapsed/refractory large B-cell lymphoma.…
NCT06919939 - New trial
Lymphoma
Phase 1 Study: Evaluating UF-KURE19 CAR-T Cells for Relapsed/Refractory B Cell NHL
Case Western is assessing the safety and manufacturing feasibility of UF-KURE19—a CD19-targeted CAR-T cell therapy modified via a shortened lentiviral process—in patients with relapsed non-Hodgkin lymphoma (with or…
NCT05400109 - Trial result
Lymphoma
Evorpacept Plus R2 Achieves Remarkable Complete Response Rates in Relapsed/Refractory B‑Cell NHL
In this phase I study of 20 patients with relapsed/refractory B‑cell non‑Hodgkin lymphoma, the combination of evorpacept (a potent CD47 blocker) with lenalidomide and rituximab demonstrated a 90% overall response…
- New trial
Lymphoma
Phase III Trial Compares Tisagenlecleucel Versus Standard Therapy in r/r Follicular Lymphoma
Novartis is leading a multi-center trial that randomizes adult r/r follicular lymphoma patients to receive either a single infusion of CD19-directed CAR-T cell therapy (tisagenlecleucel) or standard regimens (R2 or…
NCT05888493
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.